Benign prostatic hyperplasia

AUA Releases Amendment to the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline

Retrieved on: 
torsdag, september 14, 2023
PAE, Male, Prostatic artery embolization, Prevalence, Guideline, E pluribus unum, Epithelium, AUA, BPH, LUTS, Urethra, Ageing, American Urological Association, Prostate, Literature, MD, Patient, Finasteride, Water, Memorial Sloan Kettering Cancer Center, Diagnosis, Benign prostatic hyperplasia, System, ULR, Update, Medical imaging, Dietary supplement

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.
  • Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the production of smooth muscle and epithelial cells within the prostatic transition zone.
  • The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society.
  • Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023.

Seoul St. Mary's Hospital Found Red Ginseng Oil is Excellent for Improving Prostatic Hyperplasia

Retrieved on: 
torsdag, september 14, 2023
Korea Ginseng Corporation, Retention rate, Urine, BPH, KGC, International Prostate Symptom Score, Nocturia, Research, Multimedia, JUNG, Malignancy, Capsule, Professor, Patient, Hospital, Department of Urology, University of Virginia, Ageing, Benign prostatic hyperplasia, Dietary supplement, IPSS

SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.

Key Points: 
  • SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.
  • Led by Professor Kim Sae Woong from the Department of Urology at Seoul St. Mary's Hospital, in collaboration with the Korea Ginseng Corporation (KGC), this research's results indicate that the intake of red ginseng oil extracted from JUNG KWAN JANG's RXGIN can safely and effectively improve prostatic hyperplasia.
  • It turns out that, compared to a mere 3.7% improvement in the control group, the red ginseng oil group experienced a significant 50.5% improvement in the red ginseng oil group in IPSS.
  • Professor Kim explained, "We found that red ginseng oil not only significantly improves the symptoms of BPH but also enhances dysfunction, which are the side effects of existing BPH(Benign prostatic hyperplasia) treatments."

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
torsdag, augusti 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Patient satisfaction, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, Hepatic encephalopathy, Prescription, Research, Part, Oliguria, History, Government, Russell 3000 Index, Trial of the century, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Patient, Russell, Urinary retention, Cardiology, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Anuria, Security (finance), Cryptocurrency, Pharmaceutical industry, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. 

Key Points: 
  • For the second quarter ended June 30, 2023, scPharmaceuticals reports:
    Obtained national Medicaid coverage of FUROSCIX effective July 1, 2023.
  • Ended the second quarter of 2023 with cash, cash equivalents and short-term investments of $102.9 million.
  • Research and development expenses were $2.9 million for the second quarter of 2023, compared to $5.1 million for the second quarter of 2022.
  • Selling, general and administrative expenses were $12.1 million for the second quarter of 2023, compared to $4.3 million for the second quarter of 2022.

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Retrieved on: 
tisdag, augusti 1, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, US Foods, Hypoproteinemia, Organic acid, Heart failure, Chronic kidney disease, Urine, Creatinine, Cirrhosis, Dehydration, Glucose, Tinnitus, Deafness, Huber loss, Edema, Hepatic encephalopathy, Oliguria, History, Solubility, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patent, Patient, Physician, Urinary retention, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Kidney disease, Anuria, Pharmaceutical industry, Medical device

FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.

Key Points: 
  • FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.
  • “We are very pleased with the outcome of our recent Type C meeting with the FDA, and believe this paves the way for potential expansion of the FUROSCIX indication to allow for use in NYHA Class IV patients,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.
  • “We estimate that as many as 10% of all heart failure patients are Class IV, and a meaningful percentage of these – as many as 40% - may benefit from FUROSCIX.
  • FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Retrieved on: 
tisdag, juli 25, 2023
Advertising, Marketing, Pharmacy, BPH, Biotechnology, Bluewater, Patient, Risk, Benign prostatic hyperplasia, Pharmaceutical industry

CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with UpScriptHealth (“UpScript”) to generate a robust, online telemedicine platform to distribute Blue Water’s benign prostatic hyperplasia (“BPH”) asset, ENTADFI®.

Key Points: 
  • CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with UpScriptHealth (“UpScript”) to generate a robust, online telemedicine platform to distribute Blue Water’s benign prostatic hyperplasia (“BPH”) asset, ENTADFI®.
  • Under this agreement, UpScript will build an online platform to support BPH patients throughout the prescription and coverage process, as well as provide eligible patients access to ENTADFI® mailed directly to their homes.
  • This agreement with UpScript represents a milestone reached by Blue Water in its efforts to launch its commercial portfolio, highlighted by ENTADFI®, that was previously announced in a letter to shareholders from Mr. Hernandez earlier this month.
  • With the official launch of ENTADFI® scheduled in the coming months, Blue Water’s commercial team is executing on key strategies including sales force development, distribution capabilities, as well as marketing and advertising development.

Nymox Reports on U.S. Patent Issuances

Retrieved on: 
tisdag, juli 18, 2023
BPH, Anesthesia, Male, Ejaculation, Benign prostatic hyperplasia, Depression, Risk, Hypotension, DSM-IV codes, Prostate cancer, Pharmaceutical industry

IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.

Key Points: 
  • IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.
  • The Company continues to expand its patent portfolio, which is an integral part of its business.
  • In the past 18 months, numerous newly issued patents have been granted in important jurisdictions in different parts of the world, including major markets.
  • The Company's CEO and founder, Paul Averback has been the inventor responsible for the Company's technology and patents.

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

Retrieved on: 
fredag, juni 23, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, FTSE Russell, Hepatic encephalopathy, Oliguria, History, Russell Indexes, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Russell, Patient, Urinary retention, Azotemia, Ascites, Coma, Growth, Blood volume, Benign prostatic hyperplasia, Thrombosis, BUN, Cerebral edema, CO2, Anuria, Pharmaceutical industry, Cryptocurrency

The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.

Key Points: 
  • The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market capitalization rankings and style attributes.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
onsdag, maj 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Pharmacy, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Heart, Deafness, Huber loss, Edema, Food and Drug Administration, Hepatic encephalopathy, Medicare Part D, Prescription, Research, Part, Oliguria, History, Trial of the century, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Physician, Patient, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Food, Anuria, Security (finance), Pharmaceutical industry, Health insurance, Video game, Medical device, BURLINGTON

BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. 

Key Points: 
  • Ended the first quarter of 2023 with cash, cash equivalents and short-term investments of $116.1 million.
  • Net product revenues were $2.1 million and cost of product revenues were $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.1 million for the first quarter of 2023, compared to $4.3 million for the first quarter of 2022.
  • As of March 31, 2023, scPharmaceuticals’ total shares outstanding was 35,769,073.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s first quarter 2023 results today, Wednesday, May 10, at 4:30 p.m.

Nymox Provides Current Update

Retrieved on: 
onsdag, maj 10, 2023
Male, Prevalence, Marketing, BPH, Catheter, Sleep, TM, Incontinence, Anesthesia, Marketing Authorisation Application, Benign prostatic hyperplasia, Pharmaceutical industry

IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities.

Key Points: 
  • IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities.
  • The Company expects to report further details once the application is submitted, which is expected this quarter as earlier announced.
  • Nymozarfex is given once in a convenient office administration lasting a few minutes, without catheter and without anesthesia.
  • The Company will continue to keep shareholders informed on current developments in a timely manner.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Retrieved on: 
onsdag, mars 22, 2023
Hypersensitivity, Furosemide, Oaktree Capital Management, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Marketing, Creatinine, Cirrhosis, Dehydration, Tinnitus, Heart, Glucose, Huber loss, Deafness, Edema, Hepatic encephalopathy, Medicare Part D, Research, Oliguria, History, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patient, Investment, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Anuria, Pharmaceutical industry, Cryptocurrency, Security (finance), Video game, Finance, BURLINGTON

BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update. 

Key Points: 
  • Entered into $100 million secured debt financing agreement with funds managed by Oaktree Capital Management in October 2022.
  • scPharmaceuticals ended the fourth quarter 2022 with $118.4 million in cash, cash equivalents, restricted cash and investments, compared to $75.5 million as of December 31, 2021.
    scPharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2022, compared to $7.3 million for the fourth quarter of 2021.
  • Research and development expenses were $2.3 million for the fourth quarter of 2022, compared to $4.5 million for the fourth quarter of 2021.
  • General and administrative expenses were $7.2 million for the fourth quarter of 2022, compared to $2.2 million for the fourth quarter of 2021.